CGTN
30.10.2020 04:15:07 CET | Business Wire | Press release
The 19th Central Committee of the Communist Party of China (CPC) concluded its fifth plenary session in Beijing on Thursday with the release of a communique.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201029006395/en/
The 14th Five-Year Plan (FYP) (2021-2025) for National Economic and Social Development and the Long-Range Objectives Through the Year 2035 are the key topics of the communique.
Here is a look at all the highlights from the communique of the meeting.
Read the original article: here .
Decisive success made in building a moderately prosperous society in all respects
This year is the final year of China's 13th FYP period (2016-2020) and the communique highlighted that the implementation of the 13th FYP has been smooth.
By adhering to the new development concept and unswervingly advancing reform and opening-up, great achievements have been made since the fourth plenary session, the communique said.
During the past year, China has deepened supply-side reform, enhanced macro-economic regulation and expanded domestic demand as the strategic foundation.
Economic growth has been better than expected, people's livelihood has been improved and social stability has been maintained.
During the 13th FYP period, which is coming to an end in 2020, China has made great progress with stable economic growth and better economic structure, the communique said, noting China's GDP is expected to surpass the 100 trillion yuan ($14.9 trillion) mark in 2020.
More than 55 million people in China have been lifted out of poverty in the past five years.
China has built the world's largest social security system in the 13th FYP period, the communique said, adding that the country's basic medical insurance has covered over 1.3 billion people, and basic old-age insurance has covered nearly 1 billion people.
Meanwhile, during the past five years, more than 60 million new jobs were created in China's urban areas, it said.
As for the fight against the COVID-19 pandemic, the whole country coordinated the prevention and control work with economic and social development and put people's safety and health first.
Major country diplomacy with Chinese characteristics was vigorously promoted, and major achievements were made in various undertakings of the Party and state.
The strength of the leadership of the CPC and the Chinese socialist system has been further demonstrated in the past five years, it added.
New challenges, opportunities and proposals ahead
With regards to the blueprint for the future, the communique stressed that the whole Party must take into account the overall strategic plan for the great rejuvenation of the Chinese nation with major changes in the world that have not occurred in a century.
A thorough understanding is necessary about the new characteristics and requirements brought about by the changes in the evolution of the principal contradiction facing Chinese society, it said.
Also, given that China is in the primary stage of socialism, more attention should be paid to the new contradictions and challenges brought by the complex international environment.
The communique underlined the importance of strengthening awareness of opportunities and risks and cultivating opportunities amid crisis.
Additionally, the CPC has raised a set of long-range objectives for China to achieve socialist modernization by 2035.
China's economic, technological and composite strength was also stressed, as well as development in new industrialization and the modernization of China's system and capacity for governance.
The communique also said effort was needed in boosting the well-rounded development of society, including social etiquette and civility and the advancement of eco-friendly ways of work and life.
China's opening-up, per capita GDP, the implementation of the Peaceful China initiative and well-rounded human development were also highlighted.
As for the goals to be reached during the 14 FYP period, the communique said that the overall leadership of the CPC must be upheld to realize the 14th FYP and efforts should be made to mobilize all positive factors and rally all the forces that can be rallied to form a strong synergy to promote development.
Several proposals to reach the goals
- Upholding the central role of innovation in its modernization drive and implementing the innovation-driven strategy.
- Building a modern industrial system and upgrading the economic structure. It will continue to support the real economy, improve manufacturing power and modernized industrial chain and supply chain, so as to improve high-quality growth and core competitiveness.
- Nurturing a strong domestic market and establishing a new development pattern. The country will smooth domestic circulation and let domestic and international circulations reinforce each other, spurring consumption in an all-round way and expanding investment.
- Deepening reform comprehensively in pursuit of a high-level socialist market economy.
- Prioritizing the development of agriculture and rural areas, and fully advancing rural vitalization.
- Advancing coordinated regional development and a new type of urbanization.
- Promoting cultural sector and improving its cultural soft power.
- Accelerating green and low-carbon development, continuously improving the environment as well as the quality and stability of ecosystems, and raising the efficiency of resource utilization.
- Pursuing high-level opening-up and exploring new prospects of win-win cooperation.
It will continue to widen the opening-up and leverage the advantages of its huge market to promote international cooperation and achieve win-win results.
- Improving people's standard of living, and actively implementing strategies to address ageing population.
- Strengthening national security capabilities and increasing the capacity to deal with traditional and non-traditional security challenges, so as to protect people's lives and security and maintain social stability.
- Maintaining the long-term prosperity and stability of the Hong Kong and Macao special administrative regions, and promoting the reunification of Chinese mainland and Taiwan as well as peaceful Cross-Strait development.
It aims to keep a stable external environment and promote the building of a new type of international relations and a community with a shared future for mankind.
A total of 198 members and 166 alternate members of the CPC Central Committee attended the meeting.
Also present were members of the Standing Committee of the CPC Central Commission for Discipline Inspection and senior officials of relevant sectors, as well as experts, scholars and several deputies of the 19th CPC National Congress who work at the grassroots level.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201029006395/en/
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Investor Supporting Japan’s Entertainment Industry, Yoshihiro Shimamura, to Visit France Workshop to be Held During the Cannes Film Festival28.4.2026 04:00:00 CEST | Press release
Shimamura Yoshihiro Film Planning Inc. (Head Office: Osaka, Japan; CEO: Yoshihiro Shimamura), a company engaged in film production and investment, will host a workshop in France during this year’s Cannes Film Festival, as part of its commitment to further advancing the entertainment industry. The company invests in leading entertainment-related businesses in Japan and places strong emphasis on long-term value creation. It identifies the cultural and entertainment sectors as high-growth areas and is actively involved in international co-productions as a core part of its film production activities. As a recent investment, the company acquired 2,000,000 shares of Hankyu Hanshin Holdings, Inc.—a major Japanese entertainment conglomerate known for producing content enjoyed across generations—and became a major shareholder (as of March 25, 2026). Through such investments, the company aims to support the global expansion of Japanese entertainment while exploring synergies with its own interna
Alsym Energy Announces Na-Series Battery Success Developed With Physics-Informed AI Platform27.4.2026 21:25:00 CEST | Press release
Alsym’s proprietary physics-informed AI platform powered the development of its Na-Series batteries—a non-flammable, high performance and low cost energy solution positioned to serve critical energy storage markets including data centers, utilities, telecommunications, commercial real estate, industrial and defense, among others. Alsym Energy, a pioneer in non-flammable, high-performance sodium-ion batteries, today announced details of the proprietary physics-informed AI platform used to develop the company’s recently launched Na-Series sodium-ion batteries. By integrating fundamental physics models with AI, autonomous testing and proprietary molecular diagnostics in a closed-loop system, Alsym is accelerating the design of safer, inexpensive, commercialized batteries through all phases of the development cycle. As global demand for electricity surges, the limitations of lithium-ion batteries have become increasingly apparent, particularly around safety and supply chain constraints. Li
Backed by Investments Exceeding $1 Billion, PCI Pharma Services Announces Major Expansion of US Sterile Fill-Finish and Drug-Device Delivery Combination Capabilities27.4.2026 16:00:00 CEST | Press release
As pharma manufacturers prioritize US supply chain resilience, highlights include high-speed isolator filling lines for prefilled syringes, cartridges and vials, and drug-device combination assembly and packaging. PCI Pharma Services (“PCI”) – a world-leading integrated global contract development and manufacturing organization (CDMO) focused on innovative biologic and small molecule therapies – announced a series of major infrastructure investments that substantially deepen its sterile fill-finish and advanced drug delivery capabilities. As pharma manufacturers and their development partners increasingly prioritize US supply chain resilience, PCI’s latest investments come as part of a broader commitment exceeding $1 billion across the CDMO’s US and European operations, reinforcing its ability to provide seamless support for drug product development and manufacturing, clinical trial supply and drug-device combination assembly from clinical stages through commercial launch – all underpi
Pure Lithium Appoints Renowned Battery Expert Dr. Yuan Gao to Board of Directors27.4.2026 15:53:00 CEST | Press release
Pure Lithium Corporation, a vertically integrated lithium metal battery technology company, is pleased to announce that world-renowned inventor and battery expert Dr. Yuan Gao has joined the company’s Board of Directors. Dr. Gao has been an invaluable member of Pure Lithium’s Scientific Advisory Board since October of 2023. "We are thrilled to have Dr. Gao join our board as we focus on rapidly scaling our technology in the most capital efficient manner possible,” said Pure Lithium Founder, Chairman and CEO Emilie Bodoin. “Dr. Gao is a brilliant scientist who also has deep commercial expertise, a rare combination. He is also unique in the industry because his experience spans the entire battery materials value chain, including all of Pure Lithium’s verticals. His insights over the years have been critical in advancing our technology, and his experience as a director of public companies will strengthen our board.” Dr. Gao commented: “I am thrilled to join the board of Pure Lithium Corpor
Taiho Oncology, Taiho Pharmaceutical and Araris Biotech AG Advance ADC ARC-02 into Phase 1 Clinical Development27.4.2026 15:00:00 CEST | Press release
Phase 1 dose-escalation trial represents the first clinical trial of a product developed using the AraLinQ™ ADC technology and marks Taiho’s expansion into the clinical development of ADCs for oncology Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd., and Araris Biotech AG (“Araris”) today announced that the U.S. Food and Drug Administration (FDA) has completed its Investigational New Drug (IND) review period for ARC-02, an antibody-drug conjugate (ADC) being developed for the treatment of non-Hodgkin lymphoma, enabling Taiho Oncology to initiate a Phase 1 dose-escalation clinical trial of ARC-02. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427127507/en/ Taiho Pharmaceutical acquired Araris Biotech in March 2025, expanding Taiho group’s capabilities in biologics and ADC research and development. Araris is a spin-off of the Paul Scherrer Institute and ETH in Switzerland focused on the development of antibody-drug co
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
